---
layout: post
title: "Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings; Guidance for Industry; Availability"
date: 2026-02-05 18:59:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-16074
original_published: 2022-07-27 00:00:00 +0000
significance: 8.00
---

# Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 27, 2022 00:00 UTC
**Document Number:** 2022-16074

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings." The guidance provides recommendations to sponsors of clinical trials of investigational cancer drugs regarding the inclusion of patients who have not previously received available therapy (commonly referred to as existing treatment options) for their cancer in the non-curative setting. This guidance finalizes the draft guidance of the same title issued on June 24, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/27/2022-16074/cancer-clinical-trial-eligibility-criteria-available-therapy-in-non-curative-settings-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-16074

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
